Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISCT 2021 | Advances in cell-based therapies for MS

Jakob Dupont, MD, MA, Atara Biotherapeutics, San Francisco, CA, provides an overview of the current landscape for cell-based therapies for multiple sclerosis (MS). There is evidence to suggest that Epstein-Barr virus (EBV) can drive the development of autoimmune diseases such as MS. Dr Dupont describes ATA188, an allogeneic EBV-targeting T-cell immunotherapy currently being investigated for the treatment of progressive MS. Another cell-based strategy involves giving chemotherapy to patients with MS to ablate their immune system, followed by a bone marrow transplant to reconstitute it. Other stem cell-based approaches are in early phase clinical trials. This interview took place during the International Society for Cell & Gene Therapy (ISCT) Annual Meeting 2021.


Jakob Dupont is an employee of Atara Biotherapeutics, San Francisco, CA.